Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 3/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | NPY4R | P50391 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29596406 | 0.96 | MME (0.53) | MMEBACE1KISS1ROPRM1 | |
| SCHEMBL30903437 | 0.91 | BACE1 (0.51) | MMEBACE1 | |
| SCHEMBL29489420 | 0.90 | BACE1 (0.53) | MMEBACE1NPY1RNPY2RNPY4R | |
| SCHEMBL30011828 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL30011726 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL30011159 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL30010977 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL30010232 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL30011801 | 0.88 | MME (0.66) | MMEACE | |
| SCHEMBL14060524 | 0.88 | BACE1 (0.52) | MMEBACE1NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115856149-B | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-115856149-A | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-03-28 | — | — | CN | claimed |
| US-20260053884-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | PH HEALTH LIMITED (IE) | 2026-02-26 | — | — | US | disclosed |
| US-20260041729-A1 | Vasopressin Formulations for Use in Treatment Of Hypotension | PAR PHARMACEUTICAL INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12186362-B2 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-115856149-B | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-20230256048-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION | 2023-08-17 | — | — | US | disclosed |
| CN-115856149-A | Method for detecting impurities in terlipressin | 哈尔滨吉象隆生物技术有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022149159-A1 | MOLECULAR IMAGING COMPLEX FOR POSITRON EMISSION TOMOGRAPHY | SHUKLA JAYA (IN) | 2022-07-14 | — | — | WO | disclosed |
| US-20220133838-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256048-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | MME 15/4885BACE1 3489/4885NPY1R 218/4885 |
| US-12186362-B2 | Vasopressin formulations for use in treatment of hypotension | AVPR2, AVPR1B, AVPR1A | MME 15/4885BACE1 3489/4885NPY1R 218/4885 |
| US-20260041729-A1 | Vasopressin Formulations for Use in Treatment Of Hypotension | AVPR1B, AVPR2, AVPR1A | MME 487/4885BACE1 1431/4885NPY1R 347/4885 |
| US-20260053884-A1 | PEPTIDE CONGENERS WITH POLYMER EXCIPIENTS | AVPR1B, AVPR2, VIP | MME 198/4885BACE1 1435/4885NPY1R 31/4885 |
| US-20220133838-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | MME 15/4885BACE1 3489/4885NPY1R 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.